The Global Health Body Issues Alert Over Critical Scarcity of Obesity Jabs
Under one in 10 people eligible to benefit from GLP-1 drugs like Wegovy are able to get them, states the global health agency as it issues its initial advice on the drugs.
Given in excess of 1,000,000,000 individuals worldwide currently obese, it is urging increased and just access to this class of drugs.
According to estimates, over two billion are projected to be obese by 2030 without intervention.
"Our new guidance affirms that obesity is a long-term condition that can be managed with comprehensive and ongoing support," remarked the agency's head Tedros Adhanom Ghebreyesus.
Substantial prices, insufficient output, and supply-chain constraints are major barriers to broad access to the injections that can assist patients in reducing considerable weight, notes the organization.
Weight-Loss Drug Shortage
Despite the current best projected case, the production of these medications could only cover around 100 million people – less than 10% of those who need them, per the health organization.
The guideline calls on nations and manufacturers to expand availability, by measures like licensing agreements.
Exclusive production rights on the active ingredient – the main ingredient of Novo Nordisk's Wegovy – is due to expire in multiple nations in 2026.
The Way Weight-Loss Jabs Function
These medications imitate a body's own hormone to slow digestion, curb appetite and enhance the sense of being full so people consume fewer calories.
Patients commonly begin shedding pounds within a few weeks of starting on the regular doses.
Research indicates users may see weight return a year later of discontinuing the treatment, as their usual food cravings come back.
To be carrying excess weight raises your risk for contracting medical conditions, like diabetes, heart disease, stroke, and certain cancers.
Excess weight affects people in every country and was linked to over three and a half million fatalities worldwide in 2024, per the health agency.
